Literature DB >> 10409675

Mutations in the vasopressin prohormone involved in diabetes insipidus impair endoplasmic reticulum export but not sorting.

M Nijenhuis1, R Zalm, J P Burbach.   

Abstract

Familial neurohypophysial diabetes insipidus is characterized by vasopressin deficiency caused by heterozygous expression of a mutated vasopressin prohormone gene. To elucidate the mechanism of this disease, we stably expressed five vasopressin prohormones with a mutation in the neurophysin moiety (NP14G-->R, NP47E-->G, NP47DeltaE, NP57G-->S, and NP65G-->V) in the neuroendocrine cell lines Neuro-2A and PC12/PC2. Metabolic labeling demonstrated that processing and secretion of all five mutants was impaired, albeit to different extents (NP65G-->V >/= NP14G-->R > NP47DeltaE >/= NP47E-->G > NP57G-->S). Persisting endoglycosidase H sensitivity revealed these defects to be due to retention of mutant prohormone in the endoplasmic reticulum. Mutant prohormones that partially passed the endoplasmic reticulum were normally targeted to the regulated secretory pathway. Surprisingly, this also included mutants with mutations in residues involved in binding of vasopressin to neurophysin, a process implicated in targeting of the prohormone. To mimick the high expression in vasopressin-producing neurons, mutant vasopressin prohormones were transiently expressed in Neuro-2A cells. Immunofluorescence displayed formation of large accumulations of mutant prohormone in the endoplasmic reticulum, accompanied by redistribution of an endoplasmic reticulum marker. Our data suggest that prolonged perturbation of the endoplasmic reticulum eventually leads to degeneration of neurons expressing mutant vasopressin prohormones, explaining the dominant nature of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409675     DOI: 10.1074/jbc.274.30.21200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Structural Requirements for Sorting Pro-Vasopressin to the Regulated Secretory Pathway in a Neuronal Cell Line.

Authors:  David R Cool; Steven B Jackson; Karen S Waddell
Journal:  Open Neuroendocrinol J       Date:  2008-01-01

Review 3.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

4.  A novel variation in the AVP gene resulting in familial neurohypophyseal diabetes insipidus in a large Italian kindred.

Authors:  Camilla Birkegaard; Jane H Christensen; Alberto Falorni; Stefania Marzotti; Viviana Minarelli; Niels Gregersen; Søren Rittig
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

5.  Dominant-negative diabetes insipidus and other endocrinopathies.

Authors:  John A Phillips
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

6.  A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons.

Authors:  Theron A Russell; Masafumi Ito; Mika Ito; Richard N Yu; Fred A Martinson; Jeffrey Weiss; J Larry Jameson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Misfolding of Mutated Vasopressin Causes ER-Retention and Activation of ER-Stress Markers in Neuro-2a Cells.

Authors:  Zhongyu Yan; Andrea Hoffmann; Erin Kelly Kaiser; William C Grunwald; David R Cool
Journal:  Open Neuroendocrinol J       Date:  2011

8.  Functional analyses of three different mutations in the AVP-NPII gene causing familial neurohypophyseal diabetes insipidus.

Authors:  Merve Özcan Türkmen; Tugce Karaduman; Beril Erdem Tuncdemir; Mehmet Altay Ünal; Hatice Mergen
Journal:  Endocrine       Date:  2021-07-07       Impact factor: 3.633

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.